Proactive Investors
15 Jun 2026, 12:49 UTC · 1h ago
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
15 Jun 2026, 12:49 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Medicus Pharma's Phase 2 study of SkinJect showed a 64% clinical clearance rate and a 55% complete response rate in nodular basal cell carcinoma patients. — Strong clinical efficacy data in Phase 2 is a primary driver for biotech valuations and increases the probability of regulatory success.
+0.60Medicus Pharma has submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect. — Approval of this designation could lead to a Priority Review Voucher, which is a highly liquid and valuable asset that can be sold or used to accelerate other drug approvals.
+0.40SkinJect is currently awaiting a decision on an Orphan Drug Designation application and a registrational study design from the FDA. — Orphan Drug status provides significant commercial advantages, including seven years of market exclusivity and fee waivers.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company has submitted a Rare Pediatric Disease Designation request and reported positive Phase 2 clinical clearance rates for SkinJect.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
